K Stålberg1, T Svensson2, S Lönn3, H Kieler2. 1. Department of Women's and Children's Health, Uppsala University, 75185 Uppsala, Sweden. Electronic address: karin.stalberg@kbh.uu.se. 2. Centre for Pharmacoepidemiology, Department of Medicine, Karolinska Institutet, 17177 Stockholm, Sweden. 3. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 17177 Stockholm, Sweden; Research and Development, Region Halland, 30185 Halmstad, Sweden.
Abstract
BACKGROUND: Ovarian cancer is a severe disease with a peak incidence in the older age groups where concurrent morbidity is common and could potentially influence mortality rates. OBJECTIVES: The aim was to study the influence of common comorbidity diagnoses on mortality in ovarian cancer patients. METHODS: The study population was patients with ovarian cancer in Sweden 1993-2006 (n=11.139) identified in the national Cancer Register. Comorbidity data was obtained from the Patient Register and mortality from Cause of Death Register. Mortality was analyzed with Cox' proportional hazards models and subgroup analyses were performed by age and tumor histology. RESULTS: Almost all of the assessed comorbidities increased mortality in ovarian cancer patients. Thromboembolism was the most hazardous comorbidity (HR=1.95, <1 year after cancer diagnosis and HR=7.83, 1-5 years after cancer diagnosis) followed by hematologic complications (HR=1.84 and 7.11 respectively) and infectious disease (HR=1.48 and 5.28 respectively). The occurrence of diabetes mellitus and hypertension had less impact on mortality. CONCLUSION: Thromboembolism, hematologic complications and infections had a pronounced effect on mortality rates in women with ovarian cancer. The impact of comorbidity was mainly apparent among those with a more prosperous prognosis, such as longer time since cancer diagnosis, less aggressive tumors and younger age.
BACKGROUND:Ovarian cancer is a severe disease with a peak incidence in the older age groups where concurrent morbidity is common and could potentially influence mortality rates. OBJECTIVES: The aim was to study the influence of common comorbidity diagnoses on mortality in ovarian cancerpatients. METHODS: The study population was patients with ovarian cancer in Sweden 1993-2006 (n=11.139) identified in the national Cancer Register. Comorbidity data was obtained from the Patient Register and mortality from Cause of Death Register. Mortality was analyzed with Cox' proportional hazards models and subgroup analyses were performed by age and tumor histology. RESULTS: Almost all of the assessed comorbidities increased mortality in ovarian cancerpatients. Thromboembolism was the most hazardous comorbidity (HR=1.95, <1 year after cancer diagnosis and HR=7.83, 1-5 years after cancer diagnosis) followed by hematologic complications (HR=1.84 and 7.11 respectively) and infectious disease (HR=1.48 and 5.28 respectively). The occurrence of diabetes mellitus and hypertension had less impact on mortality. CONCLUSION:Thromboembolism, hematologic complications and infections had a pronounced effect on mortality rates in women with ovarian cancer. The impact of comorbidity was mainly apparent among those with a more prosperous prognosis, such as longer time since cancer diagnosis, less aggressive tumors and younger age.
Authors: Zhaomin Xu; Adan Z Becerra; Carla F Justiniano; Christopher T Aquina; Fergal J Fleming; Francis P Boscoe; Maria J Schymura; Abdulrahman K Sinno; Jessica Chaoul; Gary R Morrow; Lori Minasian; Sarah M Temkin Journal: J Surg Res Date: 2019-09-24 Impact factor: 2.192
Authors: Elisa V Bandera; Valerie S Lee; Lorna Rodriguez-Rodriguez; C Bethan Powell; Lawrence H Kushi Journal: JAMA Oncol Date: 2015-09 Impact factor: 31.777
Authors: Clary B Clish; Shelley S Tworoger; Oana A Zeleznik; A Heather Eliassen; Peter Kraft; Elizabeth M Poole; Bernard A Rosner; Sarah Jeanfavre; Amy A Deik; Kevin Bullock; Daniel S Hitchcock; Julian Avila-Pacheco Journal: Cancer Res Date: 2020-01-22 Impact factor: 12.701
Authors: Elisa V Bandera; Valerie S Lee; Bo Qin; Lorna Rodriguez-Rodriguez; C Bethan Powell; Lawrence H Kushi Journal: Br J Cancer Date: 2017-06-06 Impact factor: 7.640